2013 Archived Content
Predictive Pre-Clinical Models in Oncology
Delivering Reproducible and Predictive Results
Day 1 | Day 2 | Day 3
Friday, February 15
8:00 am Morning Coffee
8:30 Chairperson’s RemarksMelissa R. Junttila, Ph.D., Scientist, Genentech, Inc.
8:35 Targeted Kinase Inhibition: Using Pre-Clinical Data to Identify Novel Pathway Inhibitor Combinations
Barry Hart, Ph.D., VP, Project Mgmt. & Business Development, Allostem Therapeutics
Allostem Therapeutic’s lead MEK kinase inhibitor, CIP-137401, is in late pre-clinical evaluation.We believe that MEK inhibitors must be dosed in combination with other targeted therapies to have durable efficacy. As novel pathway inhibitor combinations involving MEK are reported we evaluate these for potential clinical development.
9:05 Targeting Replication Initiation in Cancer
Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.
Cdc7, an essential serine/threonine protein kinase, regulates the initiation of DNA replication to maintain genome stability. We present characterization of a potent, selective small molecule inhibitor of Cdc7 kinase activity in vitro and in vivo.
9:35 Effects of Sphingosine Kinase Activity on Tumor Cell Viability
Holger Wesche, Ph.D., Principal Scientist, Amgen, Inc.
Sphingosine kinase (SPHK) activity has been postulated to play a critical role in apoptosis. Here we report the results of studies with novel, potent and specific SPHK inhibitors which elucidate the role of S1P production in whole cells and in animals.
10:05 Applying Genetically Engineered Mouse Modeling to Oncology Drug Development
Melissa R. Junttila, Ph.D., Scientist, Genentech, Inc.
10:35 Coffee Break
10:50 The Utility of Various Imaging Modalities in Cancer Research
Simon Williams, Ph.D., Senior Scientist, Biomedical Imaging, Genentech
This talk will illustrate applications of various imaging modalities (Optical, Ultrasound, PET, CT, and MRI) in cancer research and drug development and emphasize the need to match themodality to the biological question and disease model at hand.
11:20 Metabolic PET Endpoints in Translational Oncologic Imaging: An Amgen Case Study
Charles Glaus, Ph.D., Scientist, Research Imaging Sciences, Amgen
Targeted therapeutics pose unique challenges for PET imaging biomarkers, and selection of response models and appropriate tracers is of critical importance.We present a pre-clinical PET imaging study that resulted in a focused imaging strategy for a first-in-human study.
11:50 pm Diffusion MRI for Early Detection of Treatment Response in a Pre-Clinical Glioma Model
Sharon Ungersma, Ph.D., Research Imaging Sciences, Amgen, Inc.
MRI diffusion measurements can detect cellular changes in tumor tissue.In this pre-clinical case study, we measured significant changes in MRI diffusion before differences between control and treated tumor volumes were apparent, making MRI diffusion a potential early biomarker for glioma therapy.
12:20 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:15 Chairperson’s RemarksIrina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH
1:20 Cooperative Oncology Group Banks (CGBS)
Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH
CGBs collect, store and distribute specimens from patients treated in phase III and large phase II NCI-funded randomized clinical trials.These well-annotated specimen collections are unique because they have associated uniform clinical, treatment, and outcome data.
2:50 The Role of the Biorepository in Cancer Clinical Trials: “From Bed to Bench”
Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital; Medical Director, Biopathology Center, The Research Institute at Nationwide Children’s Hospital
Biorepositories directly influence the outcome of translational research in clinical trials.They oversee procurement, banking, testing and distribution of quality clinical trial samples to approved investigators.
2:20 National Breast Cancer Biobank and Oncology Research
Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine,University of Leeds
3:50 The Role of the Tissue Bank in Academic Cancer CentersTeri A. Longacre, M.D., Professor of Pathology, Director, Tissue Procurement Facility, Stanford Cancer Center, Stanford, CaliforniaThe various functions of the tissue bank in academic cancer centers have increased in complexity in the last decade. In this lecture, key problem areas faced by academic cancer centers in the areas of tissue procurement, tissue distribution, quality metrics, accommodation of SPORE and other specific programmatic projects, clinical annotation, and data tracking are discussed. In addition, the concept of a “clinical biobank” as opposed to the traditional “research biobank” is introduced.
3:20 Close of Conference
Day 1 | Day 2 | Day 3